SENSEI BIOTHERAPEUTICS INC. - COMMON STOCK

Sensei Biotherapeutics to Participate in Cantor Fitzgerald’s Future of Oncology Virtual Symposium

30 Mar 2023 07:30:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics Reports Full Year 2022 Financial Results and Recent Business Highlights

28 Mar 2023 07:30:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics Announces Submission of Investigational New Drug (IND) Application for SNS-101, a Conditionally Active VISTA-Blocking Antibody

21 Mar 2023 07:30:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics to Present New Preclinical Data for SNS-103, a Conditionally Active Monoclonal Antibody Targeting ENTPDase1 (CD39), at the American Association for Cancer Research (AACR) Annual Meeting 2023

14 Mar 2023 16:35:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics Adopts Stockholder Rights Agreement

07 Mar 2023 17:15:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics to Participate in Oppenheimer’s 33rd Annual Healthcare Conference

06 Mar 2023 07:30:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics Presents Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Keystone Symposia on Next Generation Antibody Therapeutics

21 Feb 2023 07:30:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics to Participate in Citi’s 2023 Virtual Oncology Leadership Summit

16 Feb 2023 07:30:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics to Present New Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Keystone Symposia on Next Generation Antibody Therapeutics

14 Feb 2023 07:30:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics Signs Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) to Expand Development Plan for SNS-101, a Conditionally Active VISTA-blocking Antibody

06 Feb 2023 07:30:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics Announces Clinical Supply Agreement with Regeneron for Phase 1/2 Clinical Trial Evaluating SNS-101, a Conditionally Active VISTA-blocking Antibody, in Combination with Libtayo® (cemiplimab) in Solid Tumors

05 Jan 2023 07:30:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics Provides Update on Strategic Priorities

08 Dec 2022 07:30:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics to Participate in the Piper Sandler 34th Annual Healthcare Conference

22 Nov 2022 07:30:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics Announces Collaboration with Washington University, St. Louis to Support Development of SNS-101, a Conditionally Active VISTA-blocking Antibody

21 Nov 2022 07:30:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics Presents Preclinical Data at the 37th Society for Immunotherapy of Cancer (SITC) Annual Meeting

10 Nov 2022 09:00:03 By Nasdaq GlobeNewswire

Sensei Biotherapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights

08 Nov 2022 07:30:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics to Host Virtual Key Opinion Leader Webinar, “Lessons from VISTA: New Strategies to Address an Important Immune Checkpoint”

07 Nov 2022 07:30:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics to Participate in the 13th Annual Jefferies Global Healthcare Conference

02 Nov 2022 07:30:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics to Present New Preclinical Data at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

05 Oct 2022 08:05:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics Presents Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Sixth Annual CRI-ENCI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival

30 Sep 2022 16:05:00 By Nasdaq GlobeNewswire